Sentence: CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab ( FIRE-3 trial ) .
Drug combination annotation:
[{'class': 'POS', 'spans': ['FOLFIRI', 'cetuximab'], 'is_context_needed': True}]